Bone Therapeutics to broaden and derisk therapeutic portfolio by acquiring majority participation in Medsenic The acquisition will result in the business combination of Bone Therapeutics and Medsenic to create BioSenic, a speciality biopharma company51 percent of Medsenic shares (valued at ca EUR 40 million) to...